Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8799323 | 0.90 | THRA (0.70) | THRATHRB | |
| Axitirome SCHEMBL126256 | 0.88 | THRA (1.00) | THRATHRB | |
| Axitirome SCHEMBL29381397 | 0.88 | THRA (1.00) | THRATHRB | |
| SCHEMBL1642443 | 0.88 | THRA (0.73) | THRATHRB | |
| SCHEMBL7213670 | 0.88 | THRA (0.73) | THRATHRB | |
| SCHEMBL4965095 | 0.85 | THRA (0.72) | THRATHRB | |
| SCHEMBL7213674 | 0.85 | THRA (0.72) | THRATHRB | |
| SCHEMBL281877 | 0.82 | THRA (1.00) | THRATHRB | |
| SCHEMBL29373673 | 0.82 | THRA (1.00) | THRATHRB | |
| SCHEMBL4974242 | 0.82 | THRA (0.62) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036564-B1 | Thyromimetic antiobesity agents | PFIZER PROD INC (US) | 2004-11-17 | — | — | EP | claimed |
| US-20020035153-A1 | Thyromimetic antiobesity agents | CORNELIUS PETER (US) | 2002-03-21 | — | — | US | claimed |
| US-6344481-B1 | Thyromimetic antiobesity agents | PFIZER INC. | 2002-02-05 | — | — | US | claimed |
| EP-1036564-A1 | Thyromimetic antiobesity agents | Pfizer Products Inc. (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | claimed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | claimed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | claimed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | claimed |
| WO-2021220236-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | CADILA HEALTHCARE LIMITED (IN) | 2021-11-04 | — | — | WO | disclosed |
| US-20090076151-A1 | METHOD FOR STIMULATING WEIGHT LOSS AND/OR FOR LOWERING TRIGLYCERIDES IN PATIENTS | MORKIN EUGENE | 2009-03-19 | — | — | US | disclosed |
| US-7504435-B2 | Method for stimulating weight loss and/or for lowering triglycerides in patients | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080146668-A1 | Method for stimulating weight loss and/or for lowering triglycerides in patients | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS ("DVA") | 2008-06-19 | — | — | US | disclosed |
| EP-1036564-B1 | Thyromimetic antiobesity agents | PFIZER PROD INC (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6680340-B2 | ADMINISTERING A THYROID HORMONE RECEPTOR BETA AGONIST AND FIBRATE TO LOWER TRIGLYCERIDE LEVELS IN BLOOD | MERCK & CO., INC. | 2004-01-20 | — | — | US | disclosed |
| EP-1036564-A1 | Thyromimetic antiobesity agents | Pfizer Products Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| US-5654468-A | ANTILIPID, ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | disclosed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035153-A1 | Thyromimetic antiobesity agents | GPR119, TRHR, TSHR | THRA 5/4885THRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.